

TriTAC XR

Intact




FIG. 1A

Active




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F




FIG. 2G




FIG. 2H




FIG. 2I




FIG. 2J




FIG. 2K




FIG. 2L




FIG. 3




FIG. 4




FIG. 5




FIG. 6A






FIG. 6B




CD19-NCLV A:C:T = SEQ ID No: 3626
 CD19-NCLV A:T:C = SEQ ID No: 3627
 CD19-NCLV C:A:T = SEQ ID No: 3628
 CD19-NCLV C:T:A = SEQ ID No: 3629
 CD19-NCLV T:A:C = SEQ ID No: 3630
 CD19-NCLV T:C:A = SEQ ID No: 3631
 CD19-Stub A:C:T = SEQ ID No: 3632
 CD19-Stub A:T:C = SEQ ID No: 3633
 CD19-Stub C:A:T = SEQ ID No: 3634
 CD19-Stub C:T:A = SEQ ID No: 3635
 CD19-Stub T:A:C = SEQ ID No: 3611
 CD19-Stub T:C:A = SEQ ID No: 3636

FIG. 7




FLT3-19C-NCLV A:C:T = SEQ ID No: 3648
 FLT3-19C-NCLV A:T:C = SEQ ID No: 3649
 FLT3-19C-NCLV C:A:T = SEQ ID No: 3650
 FLT3-19C-NCLV C:T:A = SEQ ID No: 3651
 FLT3-19C-NCLV T:A:C = SEQ ID No: 3652
 FLT3-19C-NCLV T:C:A = SEQ ID No: 3653
 FLT3-19C-Stub A:C:T = SEQ ID No: 3654
 FLT3-19C-Stub A:T:C = SEQ ID No: 3655
 FLT3-19C-Stub C:A:T = SEQ ID No: 3656
 FLT3-19C-Stub C:T:A = SEQ ID No: 3657
 FLT3-19C-Stub T:A:C = SEQ ID No: 3613
 FLT3-19C-Stub T:C:A = SEQ ID No: 3658

FIG. 8



FLT3-107-NCLV A:C:T = SEQ ID No: 3637
 FLT3-107-NCLV A:T:C = SEQ ID No: 3638
 FLT3-107-NCLV C:A:T = SEQ ID No: 3639
 FLT3-107-NCLV C:T:A = SEQ ID No: 3640
 FLT3-107-NCLV T:A:C = SEQ ID No: 3641
 FLT3-107-NCLV T:C:A = SEQ ID No: 3642
 FLT3-107-Stub A:T:C = SEQ ID No: 3644
 FLT3-107-Stub C:A:T = SEQ ID No: 3645
 FLT3-107-Stub C:T:A = SEQ ID No: 3646
 FLT3-107-Stub T:A:C = SEQ ID No: 3612
 FLT3-107-Stub T:C:A = SEQ ID No: 3647

FIG. 9



NCLV A:C:T = SEQ ID No: 3614

NCLV A:T:C = SEQ ID No: 3615

NCLV C:A:T = SEQ ID No: 3616

NCLV C:T:A = SEQ ID No: 3617

NCLV T:A:C = SEQ ID No: 3618

NCLV T:C:A = SEQ ID No: 3619

Stub A:C:T = SEQ ID No: 3620

Stub A:T:C = SEQ ID No: 3621


Stub C:A:T = SEQ ID No: 3622

Stub C:T:A = SEQ ID No: 3623

Stub T:A:C = SEQ ID No: 3624


Stub T:C:A = SEQ ID No: 3625

FIG. 10



L001:αCD19:TCA = SEQ ID No: 3843
 NCLV:αCD19:TCA = SEQ ID No: 3631
 Stub:αCD19:TCA = SEQ ID No: 3636
 L001:αCD19:TAC = SEQ ID No: 3842
 NCLV:αCD19:TAC = SEQ ID No: 3630
 Stub:αCD19:TAC = SEQ ID No: 3611

FIG. 11



L001:aFLT-H19C:T:A:C = SEQ ID NO: 3854
NCLV:aFLT-H19C: T:A:C = SEQ ID NO: 3652
Stub:aFLT-H19C:T:A:C = SEQ ID NO: 3613

FIG. 12

Human CD3e Binding




FIG. 13A

Human T Cell Binding




FIG. 13B

FIG. 14A




FIG. 14B





FIG. 14C




FIG. 15




FIG. 16

Slow build-up of Active Drug and reduction of C_{max}/C_{min} ratio demonstrated in a single-dose PK study in cyno monkeys




FIG. 17

FLT3 XR /FNTA Expression in Bone Marrow from Cynos
Treated with FLT3 TriTAC-XR and TriTAC




FIG. 18

TriTAC-XR expected to have PK profile superior to IV and SC dosed TriTAC




FIG. 19

Empirical PK Profile from CD20 TriTAC-XR




FIG. 20




FIG. 21A




FIG. 21B




FIG. 22

FLT3 TriTAC-XR extends survival in EoL-1 disseminated tumor model




FIG. 23




FIG. 24

Reduced cytokine release for CD19 TriTAC-XR




FIG. 25A




FIG. 25B




FIG. 26

Slow build-up of active drug for CD20 TriTAC-XR




FIG. 27

Reduced cytokine release for CD20 TriTAC-XR




FIG. 28A




FIG. 28B

Comparable target cell depletion for
CD20 TriTAC-XR




FIG. 29




FIG. 30